Related references
Note: Only part of the references are listed.Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease
Alexander R. Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Gregory Mader et al.
BMC NEPHROLOGY (2022)
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
Shigeo Horie et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)
Kiyotaka Uchiyama et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Akinari Sekine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2020)
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD
Sravanthi Lavu et al.
JCI INSIGHT (2020)
Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease
Hyunsuk Kim et al.
NEPHROLOGY (2019)
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
Ron T. Gansevoort et al.
KIDNEY INTERNATIONAL (2019)
Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors
A. Lianne Messchendorp et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Vicente E. Torres et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease
Alan S. L. Yu et al.
KIDNEY INTERNATIONAL (2018)
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
Matthew B. Lanktree et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Polycystic kidney disease
Carsten Bergmann et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression
Monica Furlano et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
Ronald D. Perrone et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease
Young-Hwan Hwang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease
Emilie Cornec-Le Gall et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016
Fouad T. Chebib et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Evidence-based clinical practice guidelines for polycystic kidney disease 2014
Shigeo Horie et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2016)
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease
Christina M. Heyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Paola Carrera et al.
SCIENTIFIC REPORTS (2016)
Technical Evaluation: Identification of Pathogenic Mutations in PKD1 and PKD2 in Patients with Autosomal Dominant Polycystic Kidney Disease by Next-Generation Sequencing and Use of a Comprehensive New Classification System
Moritoshi Kinoshita et al.
PLOS ONE (2016)
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial
Satoru Muto et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment
Yoshiharu Tsubakihara et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2015)
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease
Haruna Kawano et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
Maria V. Irazabal et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Urinary Biomarkers at Early ADPKD Disease Stage
Katja Petzold et al.
PLOS ONE (2015)
Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease
Dongping Chen et al.
PLOS ONE (2014)
Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Kevin F. Erickson et al.
ANNALS OF INTERNAL MEDICINE (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Type of PKD1 Mutation Influences Renal Outcome in ADPKD
Emilie Cornec-Le Gall et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
Arlene B. Chapman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Autosomal dominant polycystic kidney disease: Comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients
Marie-Pierre Audrezet et al.
HUMAN MUTATION (2012)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Family History of Renal Disease Severity Predicts the Mutated Gene in ADPKD
Moumita Barua et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease
Sandro Rossetti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Autosomal dominant polycystic kidney disease
Vicente E. Torres et al.
LANCET (2007)
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Volume progression in polycystic kidney disease
JJ Grantham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study
GM Fick-Brosnahan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Share Paper
